MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Clearpath Robotics snags Intuitive Surgical design guru Hanuschik | Personnel Moves

Clearpath Robotics snags Intuitive Surgical design guru Hanuschik | Personnel Moves

By

Clearpath Robotics snags Intuitive Surgical design guru Hanuschik | Personnel MovesSelf-driving vehicle development company Clearpath Robotics said today it picked up Intuitive Surgical‘s (NSDQ:ISRG) director of design & management Mike Hanuschik.

Hanuschik led the design and product management for Intuitive Surgical’s flagship da Vinci surgical robot system, the market leading robotic surgery platform. The da Vinci is used in over 500,000 procedures annually, according to the company.

“Mike has a proven track record of building world-class teams and developing complex robot systems that are well adopted. He is an inspiring leader who knows how to create and execute an ambitious vision.  We couldn’t be more excited to have him join our executive team,” CEO Matt Rendall said in a press release.

Hanuschik started at Intuitive Surgical with no formal design education, according to a Print Magazine interview.

After leaving his job in the Navy, where he spent his time repairing displays and interfaces for fighter jets, Hanuschik found himself at a job fair Intuitive Surgical was attending. According to Hanuschik, he was offered a choice of either working on the da Vinci system, or on batteries.

He started with the Sunnyvale, Calif.-based company as a product support engineer, moving through product management to become design and management director for the da Vinci system.

Clearpath has tagged Hanuschik as its chief product officer, and said he will help establish and grow Clearpath’s Silicon Valley product design office.

“The 1st thing that stands out about Clearpath is the people. When you walk around the company, there’s a palpable sense of excitement about the work they are doing and it shows in the quality of the products they create. They clearly know how to have fun yet maintain high standards of craftsmanship and a heightened sense of urgency,” Hanuschik said.

 

 JenaValve taps Wulff for CFO
JenaValve said yesterday it has snagged ex-Pure Biosciences CFO and COO Peter Wulff for its new CFO, joining ex-Boston Scientific (NYSE:BSX) general manager Victoria Carr-Brendel who took the reins as CEO in June.
Read more

 St. Jude names Zimmer Biomet’s Dvorak to board
St. Jude Medical (NYSE:STJ) said today it has added Zimmer Biomet‘s (NYSE:ZBH) president and CEO David Dvorak to its board of directors, effective August 4.
Read more

 Ex-AxoGen exec Schiaparelli lands CEO job at Intelomed
InteloMed has named Jill Shiaparelli as its new CEO. Shiaparelli left her position as chief medical officer at AxoGen Inc. (NSDQ:AXGN) in June, to join an at-the-time ‘unnamed’ medical tech company as CEO.
Read more

 Nu-Med Plus adds Merrell as CFO
Nu-Med Plus said yesterday it tagged 30-year accounting vet Kenneth Merrell as its new CFO, replacing outgoing Mark Christensen.
Read more

 Iridex CFO Mackaness steps down
Iridex (NSDQ:IRIX) said yesterday its CFO James Mackaness, who has been with the company since 2008, has stepped down to accept a position as CFO of a different, unnamed company.
Read more

In case you missed it

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]